MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jnis-2024-022189

Медицинская библиотека · Journal of neurointerventional surgery · 2025

Stenting versus medical treatment alone for symptomatic intracranial artery stenosis: a preplanned pooled individual patient data analysis.

Wang Tao, Luo Jichang, Li Tianhua, Almallouhi Eyad, Gao Peng, Gong Haozhi, Zhang Xiao, Wang Jie, Lu Taoyuan, Yang Yifan, Yang Renjie, Xing Zixuan, Wang Haibo, Derdeyn Colin P, Jiao Liqun

СтатьяМногоцентровое исследованиеРандомизированное исследованиеСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Whether the safety and efficacy of percutaneous transluminal angioplasty and stenting (PTAS) is significantly different from that of medical treatment alone for symptomatic intracranial arterial stenosis (ICAS) is debatable. A study was undertaken to determine the safety and efficacy of both treatments for symptomatic ICAS.

METHODS

This preplanned pooled individual patient data analysis included 400 participants treated with PTAS and 409 treated with medical treatment alone in two large multicenter randomized clinical trials (SAMMPRIS and CASSISS). Patients were treated with PTAS using a self-expanding stent or medical treatment alone. The primary outcome was stroke or death within 30 days, or ischemic stroke in the territory of the qualifying artery more than 30 days after enrollment.

RESULTS

Individual data were obtained for 809 patients, 451 from SAMMPRIS and 358 from CASSISS. 400 participants were randomly assigned to the PTAS group and 409 to the medical group. The risk of the primary outcome was not significant between the PTAS and medical groups (17.5% vs 13.2%; HR 1.37 (95% CI 0.96 to 1.95), P=0.08). However, the risk of stroke or death within 30 days was higher in the PTAS group (10.5% vs 4.2%; HR 2.62 (95% CI 1.49 to 4.61), P<0.001). Patients of white ethnicity (HR 1.97, 95% CI 1.17 to 3.31) and those with hyperlipidemia (HR 2.04, 95% CI 1.27 to 3.26) or a transient ischemic attack (TIA) (HR 2.19, 95% CI 1.08 to 4.45) were at higher risk for PTAS.

CONCLUSIONS

PTAS poses an increased risk of short-term stroke/death and therefore is not advised as primary treatment for symptomatic ICAS. A balance exists between stroke risks and revascularization benefits. For patients with asymptomatic ICAS of white ethnicity and those with hyperlipidemia or a history of TIA, a thorough assessment is warranted before considering PTAS.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00576693, NCT01763320.

Для цитирования: Wang Tao, Luo Jichang, Li Tianhua, Almallouhi Eyad, Gao Peng, Gong Haozhi, Zhang Xiao, Wang Jie, Lu Taoyuan, Yang Yifan, Yang Renjie, Xing Zixuan, Wang Haibo, Derdeyn Colin P, Jiao Liqun. Stenting versus medical treatment alone for symptomatic intracranial artery stenosis: a preplanned pooled individual patient data analysis.. Journal of neurointerventional surgery. 2025. DOI: 10.1136/jnis-2024-022189.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.